title: Stage I twin-twin transfusion syndrome: rates of progression and regression in relation to outcome.
abstract: OBJECTIVE
  Twin-twin transfusion syndrome (TTTS) results in high rates of perinatal mortality and neurological morbidity. Fetoscopic laser ablation of placental anastomoses is now established as the treatment of choice for advanced disease. However, there remains controversy about its use in early-stage TTTS, in which laser-related fetal losses need to be balanced against relatively favorable outcomes with more conservative approaches. We investigated rates of progression and regression in Stage I TTTS and determined factors influencing the course of the disease.
  
  
  METHODS
  We undertook a retrospective observational study of all TTTS cases referred to our tertiary referral fetal medicine service from 2000 to 2006. In patients presenting with Stage I TTTS, the following variables were evaluated for their ability to predict the course and progression of the disease: gestational age (GA) at presentation, amniotic fluid index, recipient and donor deepest vertical pool, presence of artery-artery anastomoses, small-sized bladder compared to normal donor bladder and fetal size discordance. Study end-points were disease regression or progression, and neonatal survival at 28 days.
  
  
  RESULTS
  Among 132 consecutive cases of TTTS, 46 women presented with Stage I disease. In the majority (69.6%), disease remained stable (28.3%) or regressed (41.3%). Of cases that progressed, 79% did so within 2 weeks and 93% progressed to at least Stage III. No factor was significantly linked with progression or regression, although there was a trend towards the absence of an artery-artery anastomosis (P = 0.10) and the presence of a small rather than normal donor bladder (P = 0.10) influencing progression, and later GA at presentation (P = 0.07) influencing regression. At least one infant survived in 83% of cases and there was double survival in 59%. Perinatal outcome was significantly better in cases that regressed (the rates of at least one survivor and double survival being 89% and 89%, respectively) or remained Stage I (77% and 61%, respectively), compared with those cases that progressed (79% and 14%, respectively). Treatment with amnioreduction at first presentation did not influence progression or regression.
  
  
  CONCLUSIONS
  This study demonstrates that a high percentage of Stage I TTTS cases regress or remain early stage. Identification of factors predicting progression would facilitate the selection of patients for definitive therapy, while avoiding treatment-related morbidities in mild or transient disease.
authors.affiliation: Centre for Fetal Care, Queen Charlotte's and Chelsea Hospital, London, UK. k.odonoghue@imperial.ac.uk
authors.forename: K
authors.initials: K
authors.lastname: O'Donoghue
authors.forename: E
authors.initials: E
authors.lastname: Cartwright
authors.forename: P
authors.initials: P
authors.lastname: Galea
authors.forename: N M
authors.initials: NM
authors.lastname: Fisk
mesh_terms: D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D005330:Fetofetal Transfusion / Q000401:mortality* / Q000473:pathology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D011247:Pregnancy; D011256:Pregnancy Outcome; D012075:Remission, Spontaneous; D012189:Retrospective Studies; D015996:Survival Rate